Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
116 employees
Vedanta Biosciences: An American biotech firm pioneering microbiome immune system drugs for immune diseases.
HQ
Founded
2010
Vedanta Biosciences, founded in Cambridge, Massachusetts, is an American biotech company focused on pioneering microbiome-based therapies for immune-mediated diseases. The company's core mission is to harness the power of the human microbiome to develop novel treatments that can modulate the immune system. Vedanta's product pipeline includes drug candidates targeting conditions such as Clostridioides difficile infections and inflammatory bowel disease (IBD), utilizing a proprietary platform to create defined microbial consortia.
Notable figures associated with Vedanta Biosciences include its co-founders and key investors like Pfizer, which has significantly backed the company. Among its key achievements, Vedanta has secured $106 million in funding to advance its Phase III clinical trial for C. difficile and Phase II trial for IBD. The company's innovative approach has positioned it as a leader in the microbiome therapeutics space, aiming to transform treatment paradigms for complex immune-related conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Biotech
Technology
HealthTech, Biotech
Tags
SaaS
Model Types
Recurring
Revenue Type(s)
Enterprise
Customer Type(s)
United States, Americas
When was Vedanta Biosciences founded?
Vedanta Biosciences was founded in 2010.
Where is Vedanta Biosciences's headquarters located?
Vedanta Biosciences's headquarters is located in Cambridge, MA, US.
When was Vedanta Biosciences's last funding round?
Vedanta Biosciences's most recent funding round was for $106.5M (USD) in April 2023.
How many employees does Vedanta Biosciences have?
Vedanta Biosciences has 116 employees as of Feb 5, 2024.
How much has Vedanta Biosciences raised to-date?
As of July 05, 2023, Vedanta Biosciences has raised a total of $433.1M (USD) since Apr 25, 2023.
Add Comparison
Total Raised to Date
$433.1M
USD
Last Update Apr 25, 2023
Last Deal Details
$106.5M
USD
Apr 25, 2023
Series E
Current Employees
116
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts